Skip to main content

Advertisement

Table 1 Demographic characteristics of 7768 patients

From: Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012

  Overall 2004–06 2007–09 2010–12  
n = 7768 (%) n = 2303 (%) n = 2449 (%) N = 3016 (%) P value
Age (years)
  < 60 424 (5.5) 154 (6.7) 124 (5.1) 146 (4.8)  
 60–69 2438 (31.4) 68.4 (29.7) 739 (30.2) 1015 (33.7)  
 70–79 3825 (49.2) 1117 (48.5) 1250 (51.0) 1458 (48.3)  
  ≥ 80 1081 (13.9) 348 (15.1) 336 (13.7) 397 (13.2) 0.001
PSA at diagnosis
 10.0 or less 3729 (48.0) 963 (41.8) 1160 (47.4) 1606 (53.2)  
 10.1–20 1746 (22.5) 554 (24.1) 563 (23.0) 629 (20.9) <0.001
  > 20 2293 (29.5) 786 (34.1) 726 (29.6) 781 (25.9)  
Gleason score
 -6 2606 (33.5) 906 (39.3) 865 (35.3) 835 (27.7)  
 7 2827 (36.4) 722 (31.4) 892 (36.4) 1213 (40.2)  
 8–10 2335 (30.1) 675 (29.3) 692 (28.3) 968 (32.1) <0.001
Clinical T stage
 T1 2580 (33.2) 766 (33.3) 839 (34.3) 975 (32.3)  
 T2 3260 (42.0) 933 (40.5) 986 (40.3) 1341 (44.5)  
 T3 1544 (19.9) 489 (21.2) 489 (20.0) 566 (18.8)  
 T4 384 (4.9) 115 (5.0) 135 (5.5) 134 (4.4) 0.014
Clinical N stage
 N0 7237 (93.2) 2161 (93.8) 2278 (93.0) 2798 (92.8)  
 N1 531 (6.8) 142 (6.2) 171 (7.0) 218 (7.2) 0.296
Clinical M stage
 M0 6964 (89.6) 2019 (87.7) 2207 (90.1) 2738 (90.8)  
 M1a 25 (0.3) 11 (0.5) 6 (0.2) 8 (0.3)  
 M1b 719 (9.3) 257 (11.2) 211 (8.6) 251 (8.3)  
 M1c 60 (0.3) 16 (0.7) 25 (1.0) 19 (0.6) 0.003
Risk classification (NCCN)
 Very Low to Low 1505 (19.4) 467 (20.3) 511 (20.9) 527 (17.5)  
 Intermediate 2581 (33.2) 677 (29.4) 793 (32.4) 1111 (36.8)  
 High 2269 (29.2) 715 (31.0) 670 (27.4) 884 (29.3)  
 Locally advanced 435 (5.6) 121 (5.3) 175 (7.1) 139 (4.6)  
 Metastatic 978 (12.6) 323 (14.0) 300 (12.2) 355 (11.8) <0.001
  1. Chi-square test